查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1912793

口服TYK2抑制劑市場按適應症、分子類型、治療線、劑量強度、最終用戶和分銷管道分類－全球預測（2026-2032年）

Oral TYK2 Inhibitors Market by Indication, Molecule, Line Of Therapy, Dosage Strength, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，口服 TYK2 抑制劑市值將達到 5.6527 億美元，到 2026 年將成長至 6.1538 億美元，到 2032 年將達到 10.8027 億美元，複合年成長率為 9.69%。

主要市場統計數據
基準年 2025 5.6527億美元
預計年份：2026年 6.1538億美元
預測年份：2032年 1,080,270,000 美元
複合年成長率 (%) 9.69%

針對自體免疫疾病治療領域相關人員的口服TYK2抑制劑簡要概述：治療原理、臨床開發進展和策略挑戰

口服TYK2抑制劑已成為一個獨特的治療領域，有望改變多種免疫介導疾病的治療模式。這些小分子化合物能夠調節影響細胞激素驅動發炎的細胞內訊號傳遞，從而產生臨床療效，吸引了臨床醫生、支付者和研發人員的廣泛關注。隨著臨床計畫的成熟和監管管道的日益清晰，相關人員必須權衡徵兆、安全性、真實世界用藥依從性趨勢以及不斷變化的醫保報銷標準。

近期科學突破與競爭格局如何重塑口服TYK2抑制劑領域的治療方法與價值提案

口服TYK2抑制劑領域正經歷變革性的轉折點，這主要得益於科學技術的進步、監管里程碑的達成以及市場競爭的加劇。標靶檢驗和生物標記鑑定的進展明確了治療原理，使研發人員能夠更好地將作用機制與疾病生物學特徵結合。因此，臨床開發策略越來越重視頭對頭比較、富含生物標記的隊列研究以及長期安全性隨訪，以驗證藥物的持續療效，同時應對新出現的安全性挑戰。

評估計畫於2025年進行的關稅調整對口服TYK2療法的供應鏈、生產分配和市場進入的預期影響

2025年生效的關稅調整將對全球醫藥供應鏈產生連鎖反應，影響口服TYK2抑制劑的策略選擇。原料藥、輔料或藥品關稅的調整將增加投入成本，並促使企業重新評估製造地。因此，研發企業和契約製造可能會加快地域多角化，優先在本國或鄰近地區進行生產，以降低關稅風險並縮短前置作業時間。

從細分市場的觀點出發，主導關注臨床適應症、分子差異、治療方案、終端用戶通路、分銷管道和劑量強度。

以細分為中心的觀點揭示了在適應症、分子、治療線、終端用戶、分銷管道和劑量強度等方面最具臨床價值、商業性吸引力和營運重點的領域。適應症領域細分為克隆氏症、乾癬、乾癬性關節炎、全身性紅斑性狼瘡和潰瘍性大腸炎，其中乾癬進一步細分為慢性斑塊狀乾癬、水滴狀乾癬、反向型乾癬和膿皰型乾癬。如此廣泛的分類要求針對每種適應症和亞型製定獨特的臨床開發策略和差異化的價值提案。從分子層面來看，針對brepocitinib和deuclavacitinib的計畫展現出不同的臨床終點和安全性監測需求，這影響著標籤目標和相對於現有產品的定位。

區域策略展望：描繪美洲、歐洲、中東、非洲和亞太市場的機會輪廓以及監管、報銷和商業性的細微差別

區域趨勢將對美洲、歐洲、中東和非洲以及亞太地區的臨床開發策略、監管管道和商業模式產生重大影響。在美洲，清晰的監管環境和完善的支付方框架營造了一種氛圍，在這種氛圍下，強力的比較證據和價值論證是獲得廣泛納入處方箋的先決條件，而報銷談判往往決定著藥品上市的時機。從臨床試驗成功到廣泛應用，需要生產商準備衛生經濟學資料並規劃與支付方的早期對話。

競爭情報與合作洞察：揭示創新者、生物技術參與企業和服務供應商如何定位其投資組合、投資和市場進入策略。

口服TYK2抑制劑領域的競爭格局呈現出多元化的態勢，既有成熟的製藥企業，也有專注於生物技術的參與企業，還有合約服務供應商，各方通力合作，共同影響著藥物試驗設計、生產規模化和商業化推廣。企業面臨的主要挑戰包括：如何建立差異化的安全性和有效性聲明；如何建立完善的病患支援服務以提高病患依從性；以及如何建立能夠滿足支付方對長期價值要求的商業協議。合作與許可協議仍然是縮短研發週期和擴大地域覆蓋範圍的常用途徑，而與專科藥房和醫療系統建立策略聯盟則有助於藥物分銷和病患管理。

為行業領導者提供切實可行的優先建議，以加速技術採納、降低風險，並使臨床開發與支付方和醫療服務提供者的期望保持一致。

為了在不斷發展的口服TYK2市場中取得成功，行業領導者應優先採取一系列切實可行的步驟，將臨床差異化與實際的商業性執行相結合。首先，將比較療效終點和患者報告結果納入核心項目，以促進與支付方的溝通並展現其真實世界價值。其次，透過制定彈性價格設定和合約框架來降低支付方的風險，從而實現基於療效的協議和針對特定適應症的准入管道。第三，透過地理多元化、建立檢驗的契約製造關係以及製定應對關稅變化導致的成本波動的應急計劃，來增強生產的韌性。

本報告採用了一種透明且可重複的調查方法，詳細說明了資料來源、訪談框架、分析方法以及品質保證措施。

本報告的分析採用了混合方法，以確保研究結果的穩健性、可重複性和實用性。主要資料來源包括對臨床研究人員、支付方、專科藥劑師和行業高管的結構化訪談，以及對同行評審的臨床文獻、公開監管文件和會議報告的深入審查。負責人將定性研究結果與試驗註冊庫、安全資料庫和產品檢驗資訊進行交叉驗證，以驗證療效和安全性聲明，並確定需要進一步證據支持的領域。

本文綜合分析了在快速發展的口服TYK2治療領域中，對開發商、臨床醫生、支付者和經銷商下一步行動具有戰略意義的策略。

累積分析表明，口服TYK2抑制劑代表著一項強力的治療進展，有望重塑多種自體免疫疾病領域的治療流程。然而，要實現這一潛力，需要持續關注頭對頭臨床證據、安全性監測、與支付方的合作以及建立穩健的供應鏈。臨床差異化和廣泛的適應症將決定其應用管道，而生產和商業的靈活性將決定從核准到患者廣泛用藥的速度。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 口服TYK2抑制劑市場依適應症分類

  • 克隆氏症
  • 銀屑病
    • 慢性尋常性乾癬
    • 水滴狀乾癬
    • 反向型乾癬
    • 膿皰型乾癬
  • 乾癬性關節炎
  • 全身性紅斑性狼瘡
  • 潰瘍性大腸炎

9. 口服TYK2抑制劑市場（依分子類型分類）

  • 布雷波替尼
  • 杜克拉伐替尼

10. 按治療領域分類的口服TYK2抑制劑市場

  • 一線治療
  • 二線治療
  • 三線治療

11. 依劑量強度分類的口服TYK2抑制劑市場

  • 3mg
  • 6mg

第12章 依最終用戶分類的口服TYK2抑制劑市場

  • 醫院
  • 網路藥房
  • 零售藥房
  • 專科診所

13. 口服TYK2抑制劑市場按分銷管道分類

  • 直銷
  • 第三方經銷商

14. 各地區口服TYK2抑制劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 口服TYK2抑制劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國口服TYK2抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國口服TYK2抑制劑市場

17. 中國口服TYK2抑制劑市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alumis Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Celon Pharma SA
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-AE420CB13AA0

The Oral TYK2 Inhibitors Market was valued at USD 565.27 million in 2025 and is projected to grow to USD 615.38 million in 2026, with a CAGR of 9.69%, reaching USD 1,080.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 565.27 million
Estimated Year [2026] USD 615.38 million
Forecast Year [2032] USD 1,080.27 million
CAGR (%) 9.69%

A concise orientation to oral TYK2 inhibitors framing therapeutic rationale, clinical development momentum, and strategic imperatives for stakeholders across autoimmune care

Oral TYK2 inhibitors have emerged as a distinct therapeutic class with the potential to shift treatment paradigms across multiple immune-mediated disorders. These small molecules modulate intracellular signaling cascades that influence cytokine-driven inflammation, producing clinical responses that have attracted attention from clinicians, payers and developers alike. As clinical programs mature and regulatory pathways clarify, stakeholders must balance efficacy signals against safety profiles, real-world adherence dynamics and evolving reimbursement criteria.

This executive summary synthesizes contemporary clinical, commercial and regulatory trends relevant to oral TYK2 development and commercialization. It explores how mechanism-specific differentiation influences indication prioritization, how trial designs are adapting to competitive benchmarks, and how manufacturing and distribution considerations influence go-to-market readiness. The intent is to equip decision-makers with a concise, evidence-informed perspective that supports strategic prioritization, partnership diligence and operational planning. Transitioning from clinical potential to sustainable market access will require coordinated action across R&D, medical affairs, supply chain and commercial teams.

How recent scientific breakthroughs and competitive dynamics are reshaping therapeutic approaches and value propositions in the oral TYK2 inhibitor landscape

The oral TYK2 landscape is undergoing transformative shifts driven by scientific refinement, regulatory milestones and marketplace competition. Advances in target validation and biomarker identification have sharpened the therapeutic rationale, enabling developers to better match mechanism of action with disease biology. As a result, clinical development strategies increasingly emphasize head-to-head comparators, biomarker-enriched cohorts and extended safety follow-up to demonstrate durable benefit while addressing emergent safety questions.

Concurrently, commercialization strategies are evolving. Payers demand robust health economics evidence and comparative effectiveness data, incentivizing manufacturers to design value-based access approaches and outcomes-linked agreements. Providers are adapting treatment algorithms as oral options deliver convenience and acceptable safety relative to injectable biologics. Moreover, the entry of multiple oral agents into similar therapeutic niches has intensified the need for clear differentiation across efficacy, safety, dosing convenience and patient support services. Taken together, these dynamics are accelerating a more clinical- and commercially-driven maturation of the field, encouraging faster translation from trial evidence to real-world adoption.

Assessing the projected reverberations of United States tariff policy changes in 2025 on supply chains, manufacturing allocation and market access for oral TYK2 therapies

Policy changes to tariff regimes in the United States in 2025 will reverberate across global pharmaceutical supply chains and influence strategic choices for oral TYK2 therapies. Tariff adjustments on active pharmaceutical ingredients, excipients or finished formulations raise input costs and create incentives to reassess manufacturing footprints. Consequently, developers and contract manufacturers may accelerate regionalization of production, favoring onshore or nearshore facilities to mitigate customs exposure and reduce lead-time risks.

Beyond manufacturing allocation, tariffs affect procurement strategies for distributors and health systems, which may respond by layering inventory buffers or consolidating suppliers to manage cost volatility. These shifts can introduce short-term operational complexity and create negotiation leverage for large purchasers, while smaller providers face greater supply risk. Regulatory and trade compliance functions will need to work in tandem with commercial teams to articulate total-cost-of-care implications to payers and to structure contracting that accounts for potential input cost variability. In sum, tariff changes act as a forcing function prompting upstream resilience investments and downstream contracting adaptations that will shape market entry and scale-up plans.

Segmentation-driven perspectives highlighting clinical indications, molecular differentiation, therapy lines, end-user channels, distribution pathways and dosage strengths

A segmentation-centric view reveals where clinical value, commercial traction and operational focus are most concentrated across indications, molecules, therapy lines, end users, distribution pathways and dosage strengths. Based on Indication, the landscape spans Crohn's Disease, Psoriasis, Psoriatic Arthritis, Systemic Lupus Erythematosus, and Ulcerative Colitis, with Psoriasis further parsed into Chronic Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, and Pustular Psoriasis; this breadth requires distinct clinical development strategies and differentiated value propositions for each indication and subtype. Based on Molecule, programs focused on Brepocitinib and Deucravacitinib exhibit different clinical endpoints and safety monitoring needs, which in turn shape labeling aspirations and relative positioning versus incumbents.

Based on Line Of Therapy, adoption pathways differ substantially between First Line, Second Line, and Third Line use, with payers and clinicians exercising different thresholds for switching from established biologics. Based on End User, channel dynamics vary because Hospitals, Online Pharmacies, Retail Pharmacies, and Specialty Clinics each present unique procurement practices, distribution requirements and patient support expectations. Based on Distribution Channel, choices between Direct Sales and Third-Party Distributors alter margin structures, service capabilities and control over patient experience. Finally, Based on Dosage Strength, offering 3 mg and 6 mg options creates flexibility for titration and label breadth but also adds manufacturing complexity. Integrating these segmentation layers enables prioritization of clinical indications, channel strategies and operational investments that align with both payer requirements and provider workflows.

Regional strategic outlook mapping opportunity contours and regulatory, reimbursement and commercial nuances across the Americas, EMEA and Asia-Pacific markets

Regional dynamics will materially influence clinical development strategies, regulatory pathways and commercial models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory clarity and established payer frameworks create an environment where robust comparative evidence and value demonstration are prerequisites for broad formulary access, and where reimbursement negotiations will frequently determine uptake timelines. Transitioning from clinical trial success to widespread usage requires manufacturers to plan for health economic dossiers and to engage in early payer dialogue.

In Europe, Middle East & Africa, heterogeneous regulatory landscapes and divergent payer capabilities demand region-specific strategies that blend centralized regulatory filings with targeted country-level evidence generation. Market access pathways often hinge on cost-effectiveness assessments and negotiated pricing. By contrast, the Asia-Pacific region presents a mix of advanced markets with fast adopter clinicians and emerging systems that prioritize affordability and local manufacturing; partnership approaches and technology transfer are particularly salient for accelerated penetration. Recognizing these regional distinctions enables sponsors to sequence filings, design localized real-world evidence programs, and tailor commercial operations to meet the nuanced expectations of payers, providers and patients across geographies.

Competitive and partnership intelligence revealing how innovators, biotech entrants and service providers position portfolios, investments and go-to-market strategies

Competitive dynamics in the oral TYK2 arena reflect a mix of established pharmaceutical developers, specialized biotech entrants and contract service providers that together influence trial design, manufacturing scale-up and commercial rollout. Key corporate imperatives include securing differentiated safety and efficacy claims, establishing robust patient support services to enhance adherence, and structuring commercial agreements that address payer demands for long-term value. Partnerships and licensing arrangements remain a common route to accelerate development timelines or expand geographic reach, while strategic alliances with specialty pharmacies and healthcare systems support distribution and patient management.

Companies that prioritize integrated evidence generation-combining randomized trial data with pragmatic real-world studies and health economics analyses-tend to move more efficiently from approval to adoption. Likewise, those that invest early in scalable manufacturing and diversified supply networks reduce execution risk associated with regulatory inspections, raw material variability and trade policy shifts. Observing competitor positioning across clinical registries, label claims and service offerings reveals which players are targeting formulary leadership versus niche, specialty adoption. These patterns should guide partnership diligence, M&A assessments and commercial resource allocation.

Practical and prioritized recommendations for industry leaders to accelerate adoption, mitigate risk, and align clinical development with payer and provider expectations

To succeed in the evolving oral TYK2 market, industry leaders should prioritize a set of actionable measures that align clinical differentiation with pragmatic commercial execution. First, embed comparative-effectiveness endpoints and patient-reported outcomes into pivotal programs to facilitate payer discussions and to substantiate real-world value. Second, develop flexible pricing and contracting frameworks that allow for outcomes-based agreements or indication-specific access pathways to address payer risk aversion. Third, invest in manufacturing resilience through geographic diversification, validated contract manufacturing relationships and contingency planning for tariff-driven cost volatility.

Further, align medical affairs and commercial functions around condition-specific education for prescribers and patients, emphasizing safety management, adherence support and dosing convenience. Establish early health economics modeling and generate localized real-world evidence in priority geographies to shorten time-to-reimbursement decisions. Finally, pursue partnerships with specialty distribution channels and digital health providers to create integrated care pathways that enhance initiation and persistence. Executing these steps in a coordinated manner will reduce commercial friction, accelerate uptake among target patient cohorts, and improve the likelihood of favorable reimbursement outcomes.

Transparent and reproducible research methodology detailing data sources, interview frameworks, analytical approaches and quality assurance applied to this report

The analysis underpinning this report used a mixed-methods approach to ensure findings are robust, reproducible and actionable. Primary inputs included structured interviews with clinical investigators, payers, specialty pharmacists and industry executives, complemented by detailed review of peer-reviewed clinical literature, public regulatory filings and conference disclosures. Analysts triangulated qualitative insights with trial registries, safety databases and product labeling to cross-validate efficacy and safety narratives and to identify gaps requiring further evidence generation.

Analytical techniques incorporated comparative-effectiveness synthesis, scenario analysis for supply chain disruption and thematic coding of stakeholder interviews to identify access barriers. Quality assurance steps involved independent review of key assumptions, sensitivity checks on critical inferences and validation sessions with subject-matter experts. Where evidence gaps exist, the methodology highlights them explicitly and recommends targeted primary research to resolve uncertainties. This disciplined approach ensures that conclusions reflect both clinical realities and commercial practicability.

Synthesis of strategic implications underscoring next steps for developers, clinicians, payers and distributors in a rapidly evolving oral TYK2 treatment environment

The cumulative analysis underscores that oral TYK2 inhibitors represent a credible therapeutic advance with the potential to reshape treatment algorithms across multiple autoimmune indications. However, realizing that potential will require sustained emphasis on head-to-head clinical evidence, safety monitoring, payer engagement and resilient supply chain design. Clinical differentiation and label breadth will dictate adoption pathways, while manufacturing and commercial agility will determine the speed at which therapies move from approval to meaningful patient access.

In closing, stakeholders should approach the market with both strategic rigor and operational pragmatism: align development programs to generate the comparative and economic evidence that payers require, design commercial models that reflect regional access realities, and build supply chains that can withstand policy and trade volatility. By doing so, developers and partners will be better positioned to translate clinical promise into durable therapeutic impact for patients living with autoimmune disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral TYK2 Inhibitors Market, by Indication

  • 8.1. Crohn's Disease
  • 8.2. Psoriasis
    • 8.2.1. Chronic Plaque Psoriasis
    • 8.2.2. Guttate Psoriasis
    • 8.2.3. Inverse Psoriasis
    • 8.2.4. Pustular Psoriasis
  • 8.3. Psoriatic Arthritis
  • 8.4. Systemic Lupus Erythematosus
  • 8.5. Ulcerative Colitis

9. Oral TYK2 Inhibitors Market, by Molecule

  • 9.1. Brepocitinib
  • 9.2. Deucravacitinib

10. Oral TYK2 Inhibitors Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line

11. Oral TYK2 Inhibitors Market, by Dosage Strength

  • 11.1. 3 Mg
  • 11.2. 6 Mg

12. Oral TYK2 Inhibitors Market, by End User

  • 12.1. Hospitals
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies
  • 12.4. Specialty Clinics

13. Oral TYK2 Inhibitors Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Third-Party Distributors

14. Oral TYK2 Inhibitors Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Oral TYK2 Inhibitors Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Oral TYK2 Inhibitors Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Oral TYK2 Inhibitors Market

18. China Oral TYK2 Inhibitors Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Alumis Inc.
  • 19.7. Amgen Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. BeiGene, Ltd.
  • 19.10. Bristol-Myers Squibb Company
  • 19.11. Celon Pharma S.A.
  • 19.12. Eli Lilly and Company
  • 19.13. Galapagos NV
  • 19.14. Gilead Sciences, Inc.
  • 19.15. Incyte Corporation
  • 19.16. Johnson & Johnson
  • 19.17. Merck & Co., Inc.
  • 19.18. Novartis AG
  • 19.19. Pfizer Inc.
  • 19.20. Pfizer Inc.
  • 19.21. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL TYK2 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL TYK2 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ORAL TYK2 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ORAL TYK2 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY CHRONIC PLAQUE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY CHRONIC PLAQUE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY CHRONIC PLAQUE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY GUTTATE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY GUTTATE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY INVERSE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY INVERSE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY PUSTULAR PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY PUSTULAR PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY BREPOCITINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY BREPOCITINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY BREPOCITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY DEUCRAVACITINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY DEUCRAVACITINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY DEUCRAVACITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY 3 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY 3 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY 3 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY 6 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY 6 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY 6 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY THIRD-PARTY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY THIRD-PARTY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY THIRD-PARTY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ORAL TYK2 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. G7 ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 179. G7 ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. NATO ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. NATO ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 187. NATO ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. NATO ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ORAL TYK2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ORAL TYK2 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ORAL TYK2 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ORAL TYK2 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA ORAL TYK2 INHIBITORS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ORAL TYK2 INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ORAL TYK2 INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA ORAL TYK2 INHIBITORS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA ORAL TYK2 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA ORAL TYK2 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)